XML 31 R22.htm IDEA: XBRL DOCUMENT
v3.22.1

Liabilities Related to Sales of Future Royalties (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2022
Other Liabilities Disclosure [Abstract] |
Schedule of Purchase and Sale Agreement | In 2012 and 2020, we sold to RPI Finance Trust (RPI) and entities managed by Healthcare Royalty Management, LLC (collectively, HCR), respectively, our rights to receive royalties under our license and manufacturing agreements with certain pharmaceutical partners as summarized below under the 2012 Purchase and Sale Agreement and the 2020 Purchase and Sale Agreement, respectively:
Drug | Manufacturer | Counterparty under Purchase and Sale Agreement | Date Sold
ADYNOVATE® and ADYNOVI® (brand name for ADYNOVATE® in Europe) | Takeda Pharmaceutical Company Limited | Healthcare Royalty Management, LLC | December 16, 2020
MOVANTIK® (naloxegol tablets) and MOVENTIG® (brand name for MOVANTIK® in Europe) | AstraZeneca AB | Healthcare Royalty Management, LLC | December 16, 2020
REBINYN® | Novo Nordisk Inc., Novo Nordisk A/S and Novo Nordisk A/G | Healthcare Royalty Management, LLC | December 16, 2020
CIMZIA® (certolizumab pegol) | UCB Pharma | RPI Finance Trust | February 24, 2012
MIRCERA® (Continuous Erythropoietin Receptor Activator) | F. Hoffmann-La Roche Ltd | RPI Finance Trust | February 24, 2012
Schedule Of Liability Related To Sale Of Potential Future Royalties | The following table shows the activity within the liability account of each arrangement (in thousands):
| Period from inception to March 31, 2022
| 2012 Purchase and Sale Agreement |  | 2020 Purchase and Sale Agreement |  | Total
Royalty monetization proceeds | $ | 124,000 |  |  | $ | 150,000 |  |  | $ | 274,000 |
Non-cash royalty revenue | (289,655) |  |  | (61,357) |  |  | (351,012) |
Non-cash interest expense | 226,506 |  |  | 25,296 |  |  | 251,802 |
Payments to RPI | (10,000) |  |  | — |  |  | (10,000) |
Loss on revaluation of liability related to the sale of future royalties (1) | 23,522 |  |  | — |  |  | 23,522 |
Liabilities related to the sales of future royalties – ending balance | 74,373 |  |  | 113,939 |  |  | 188,312 |
Less: unamortized transaction costs | — |  |  | (2,708) |  |  | (2,708) |
Liabilities related to the sales of future royalties, net | $ | 74,373 |  |  | $ | 111,231 |  |  | $ | 185,604 |
(1) Loss recognized from Settlement Agreement to resolve UCB’s challenges to our patents, as agreed to by UCB, RPI and us, on October 13, 2021.

X
- Definition Schedule Of Liability Related To Sale Of Potential Future Royalties + References No definition available. + Details
Name: | nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock
Namespace Prefix: | nktr_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Schedule of Purchase and Sale Agreement [Table Text Block] + References No definition available. + Details
Name: | nktr_ScheduleOfPurchaseAndSaleAgreementTableTextBlock
Namespace Prefix: | nktr_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_OtherLiabilitiesDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration